Comprehensive Investigation of Angiogenesis, PASS Score and Immunohistochemical Factors in Risk Assessment of Malignancy for Paraganglioma and Pheochromocytoma.

Autor: Milinkovic M; Department of Pathology, University Clinical Center of Serbia, 11000 Belgrade, Serbia., Soldatovic I; Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia., Zivaljevic V; Clinic for Endocrine Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia., Bozic V; Department of Pathology, University Clinical Center of Serbia, 11000 Belgrade, Serbia., Zivotic M; Institute of Pathology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia., Tatic S; Institute of Pathology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia., Dundjerovic D; Institute of Pathology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Jazyk: angličtina
Zdroj: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2024 Apr 19; Vol. 14 (8). Date of Electronic Publication: 2024 Apr 19.
DOI: 10.3390/diagnostics14080849
Abstrakt: A challenging task in routine practice is finding the distinction between benign and malignant paragangliomas and pheochromocytomas. The aim of this study is to conduct a comparative analysis of angiogenesis by assessing intratumoral microvascular density (MVD) with immunohistochemical (IHC) markers (CD31, CD34, CD105, ERG), and S100 immunoreactivity, Ki67 proliferative index, succinate dehydrogenase B (SDHB) expressiveness, tumor size with one the most utilized score Pheochromocytoma of Adrenal Gland Scales Score (PASS), using tissue microarray (TMA) with 115 tumor samples, 61 benign (PASS < 4) and 54 potentially malignant (PASS ≥ 4). We found no notable difference between intratumoral MVD and potentially malignant behavior. The group of potentially malignant tumors is significantly larger in size, has lower intratumoral MVD, and a decreased number of S100 labeled sustentacular cells. Both groups have low proliferative activity (mean Ki67 is 1.02 and 1.22, respectively). Most tumors maintain SDHB expression, only 6 cases (5.2%) showed a loss of expression (4 of them in PASS < 4 group and 2 in PASS ≥ 4). PASS score is easily available for assessment and complemented with markers of biological behavior to complete the risk stratification algorithm. Size is directly related to PASS score and malignancy. Intratumoral MVD is extensively developed but it is not crucial in evaluating the malignant potential.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje